• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Calyxt Inc. (Amendment)

    2/14/22 6:04:59 AM ET
    $CLXT
    Agricultural Chemicals
    Industrials
    Get the next $CLXT alert in real time by email
    SC 13G/A 1 brhc10033949_sc13ga.htm SC13G/A

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*

    Calyxt, Inc.
    (Name of Issuer)

    Common stock, par value $0.0001 per share
    (Title of Class of Securities)

    13173L107
    (CUSIP Number)

    December 31, 2021
    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    CUSIP No.

    1
    NAMES OF REPORTING PERSONS
     
     
     
    Nikko Asset Management Americas, Inc.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     
    USA
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
     0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
     0
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
     0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
     
    1,326,256
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     
    1,326,256
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
     
    3.44%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
     
    IA
     
     
     
     


    Item 1.

     
    (a)
    Name of Issuer
     
    Calyxt, Inc.
         
     
    (b)
    Address of Issuer’s Principal Executive Offices
     
    2800 Mount Ridge Road, Roseville, MN 55113

    Item 2.

     
    (a)
    Name of Person Filing
       
     
    Nikko Asset Management Americas, Inc.
         
     
    (b)
    Address of Principal Business Office or, if none, Residence
       
     
    605 Third Avenue, 38th Floor, New York, NY 10158
         
     
    (c)
    Citizenship
       
     
    USA
         
     
    (d)
    Title of Class of Securities
       
     
    Common stock, par value $0.0001 per share
         
     
    (e)
    CUSIP Number
       
     
    13173L107

    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     
    (a)
    ☐
    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
           
     
    (b)
    ☐
    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
           
     
    (c)
    ☐
    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
           
     
    (d)
    ☐
    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
           
     
    (e)
    ☒
    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
     
    (f)
    ☐
    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
     
    (g)
    ☐
    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
           
     
    (h)
    ☐
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
     
    (i)
    ☐
    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
     
    (j)
    ☐
    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J).
           
     
    (k)
    ☐
    A group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:


    Item 4.
    Ownership.

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     
    (a)
    Amount beneficially owned:
         
     
    1,326,256
     
     
    (b)
    Percent of class:
         
     
    3.44%
     
     
    (c)
    Number of shares as to which the person has:
           
       
    (i)
    Sole power to vote or to direct the vote:
         
     
    0
     
       
    (ii)
    Shared power to vote or to direct the vote:
         
     
    0
     
       
    (iii)
    Sole power to dispose or to direct the disposition of:
         
     
    0
     
       
    (iv)
    Shared power to dispose or to direct the disposition of:
         
     
    1,326,256

    Item
    5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.

    Item
    6. Ownership of More than Five Percent on Behalf of Another Person.

    See Exhibit A.

    Item
    7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

    See Exhibit A.

    Item
    8. Identification and Classification of Members of the Group

    Not Applicable.

    Item
    9. Notice of Dissolution of Group

    Not Applicable.


    Item
    10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: February 11, 2022
    By:
    /s/ Gary L. Beckham
       
    Name: Gary L. Beckham
       
    Title: Chief Compliance Officer

    Attention:
    Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)


    Exhibit A

    Pursuant to the instructions in Items 6 and 7 of Schedule 13G, the security being reported on by Nikko Asset Management Americas, Inc., as subsidiary to the parent holding companies listed below, are owned, or may be deemed to be beneficially owned, by its parent holding companies.


    1)
    Sumitomo Mitsui Trust Holdings Inc.

    o
    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

    o
    A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J).


    2)
    Nikko Asset Management Co., Ltd.

    o
    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

    o
    A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J).


    Get the next $CLXT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CLXT

    DatePrice TargetRatingAnalyst
    3/4/2022$6.00 → $4.00Buy
    Canaccord Genuity
    11/2/2021$10.00Buy
    ROTH Capital
    More analyst ratings

    $CLXT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer

      EMERYVILLE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent DNA-encoded libraries and AI tools, today announced the appointment of Simon Harnest, MSc, BSc, as Chief Financial Officer. This key addition comes at a pivotal moment for Totus as the company prepares to advance its clinical-stage program following encouraging results from its Phase 1 study of TOS-358, a covalent PI3Kα inhibitor. "The addition of Simon, with over 15 years' experience in private capital markets strategy and IPO processes, comes at the right time for Totus as we advance our clinical-stage and discovery programs," said

      1/28/25 8:00:00 AM ET
      $CBUS
      $CLLS
      $MGX
      $CLXT
      Agricultural Chemicals
      Industrials
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Calyxt Announces Stockholder Approval of Merger With Cibus

      -- Calyxt Announces 1-for-5 Reverse Stock Split of Common Stock -- ROSEVILLE, Minn., May 19, 2023 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT) ("Calyxt" or the "Company") today announced the results of the special meeting of its stockholders held on May 18, 2023. At the special meeting, Calyxt's stockholders voted in favor of all proposals, including the proposal to approve the issuance of shares of Class A common stock and Class B common stock to the equity holders of Cibus Global, LLC ("Cibus") as part of the previously announced proposed merger with Cibus. The closing of the merger is anticipated to take place on or around Wednesday, May 31, 2023, subject to the satisfaction of the remainin

      5/19/23 4:01:00 PM ET
      $CLXT
      Agricultural Chemicals
      Industrials
    • Calyxt Reports First Quarter 2023 Financial Results and Provides Corporate Update

      —Proposed merger with Cibus Global Expected to Close in Q2 2023— —1-for-10 reverse stock split executed— —Current customer projects under development are on track— —Evologic Technologies completed initial phase of project to scale production of Calyxt's Plant Cell Matrix™ and BioFactoryTM technologies— ROSEVILLE, Minn., May 1, 2023 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT), a plant-based synthetic biology company, today announced operating and financial results for its first quarter ended March 31, 2023. Merger Agreement with Cibus On January 17, 2023, Calyxt announced it had entered into a definitive merger agreement (the Merger Agreement) with Cibus Global, LLC (Cibus), a leader in precis

      5/1/23 4:01:00 PM ET
      $CLXT
      Agricultural Chemicals
      Industrials

    $CLXT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Canaccord Genuity reiterated coverage on Calyxt with a new price target

      Canaccord Genuity reiterated coverage of Calyxt with a rating of Buy and set a new price target of $4.00 from $6.00 previously

      3/4/22 8:44:27 AM ET
      $CLXT
      Agricultural Chemicals
      Industrials
    • ROTH Capital initiated coverage on Calyxt with a new price target

      ROTH Capital initiated coverage of Calyxt with a rating of Buy and set a new price target of $10.00

      11/2/21 8:38:36 AM ET
      $CLXT
      Agricultural Chemicals
      Industrials
    • Canaccord Genuity resumed coverage on Calyxt with a new price target

      Canaccord Genuity resumed coverage of Calyxt with a rating of Buy and set a new price target of $16.00

      2/22/21 7:29:33 AM ET
      $CLXT
      Agricultural Chemicals
      Industrials

    $CLXT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Calyxt Inc. (Amendment)

      SC 13G/A - Cibus, Inc. (0001705843) (Subject)

      2/9/24 8:50:20 AM ET
      $CLXT
      Agricultural Chemicals
      Industrials
    • SEC Form SC 13G filed by Calyxt Inc.

      SC 13G - Cibus, Inc. (0001705843) (Subject)

      7/10/23 10:20:11 AM ET
      $CLXT
      Agricultural Chemicals
      Industrials
    • SEC Form SC 13D filed by Calyxt Inc.

      SC 13D - Cibus, Inc. (0001705843) (Subject)

      6/12/23 5:28:58 PM ET
      $CLXT
      Agricultural Chemicals
      Industrials

    $CLXT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Riggs Rory B disposed of 39,476 shares and bought $5,470,992 worth of shares (517,107 units at $10.58), increasing direct ownership by 47% to 1,622,495 units (SEC Form 4)

      4 - Cibus, Inc. (0001705843) (Issuer)

      12/14/23 5:10:06 PM ET
      $CLXT
      Agricultural Chemicals
      Industrials

    $CLXT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Riggs Rory B converted options into 1,500,000 shares and acquired 1,505,967 units of Class B Common Stock, increasing direct ownership by 128% to 3,103,788 units (SEC Form 4)

      4 - Cibus, Inc. (0001705843) (Issuer)

      1/3/24 7:08:08 PM ET
      $CLXT
      Agricultural Chemicals
      Industrials
    • Riggs Rory B disposed of 39,476 shares and bought $5,470,992 worth of shares (517,107 units at $10.58), increasing direct ownership by 47% to 1,622,495 units (SEC Form 4)

      4 - Cibus, Inc. (0001705843) (Issuer)

      12/14/23 5:10:06 PM ET
      $CLXT
      Agricultural Chemicals
      Industrials
    • SEC Form 3: New insider Collins James C. Jr. claimed no ownership of stock in the company

      3 - Cibus, Inc. (0001705843) (Issuer)

      9/25/23 4:49:52 PM ET
      $CLXT
      Agricultural Chemicals
      Industrials

    $CLXT
    Financials

    Live finance-specific insights

    See more
    • Calyxt Reports Third Quarter 2022 Financial Results and Provides Corporate Update

      —Successfully produced squalene, an important ingredient for personal care products and vaccine adjuvants— —Continued to progress customer acquisition activities, including evaluating an incremental 37 customer chemistries for development using PlantSpring™ and BioFactory™ technologies— —Signed agreement with Evologic Technologies to further develop and scale production of its Plant Cell Matrix™ technology platform— —Continuing board-level evaluation of a full range of potential strategic alternatives to maximize shareholder value— —Selected for membership to BioMADE, a Department of Defense-sponsored initiative that brings together industrial, academic and non-profit entities to advance US

      11/3/22 4:01:00 PM ET
      $CLXT
      Agricultural Chemicals
      Industrials
    • Calyxt to Host Third Quarter 2022 Financial Results Conference Call and Webcast on Thursday, November 3, 2022, at 4:30 p.m. Eastern Time

      ROSEVILLE, Minn., Oct. 27, 2022 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT), a plant-based synthetic biology company, will host a conference call and webcast on Thursday, November 3, 2022, at 4:30 p.m. ET to discuss results for the third quarter ended September 30, 2022. A press release detailing these results will be issued prior to the call. President and Chief Executive Officer, Michael A. Carr, and Chief Financial Officer, Bill Koschak, will host the conference call. The conference call will be webcast and can be accessed via the investor relations section of the Company's

      10/27/22 7:00:00 AM ET
      $CLXT
      Agricultural Chemicals
      Industrials
    • Calyxt Reports Second Quarter 2022 Financial Results and Provides Corporate Update

      Evaluated nine new customer demand-driven plant-based chemistries in the quarter, bringing cumulative chemistries evaluated for development to 95, of these 31 meet Calyxt's target profile and several are the subject of term sheet discussions Engineering solution for a high-value molecule planned to be delivered in early 2023 to a large global consumer packaged goods company Progressing discussions with multiple potential infrastructure partners who would produce chemistries in various sizes of bioreactors from pilot to commercial scale Evaluating term sheets for technology licensing and for licensing of traits Management to host conference call and webcast today at 4:30 p.m. ET ROSEVILLE, Mi

      8/4/22 4:01:00 PM ET
      $CLXT
      Agricultural Chemicals
      Industrials

    $CLXT
    Leadership Updates

    Live Leadership Updates

    See more
    • Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer

      EMERYVILLE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent DNA-encoded libraries and AI tools, today announced the appointment of Simon Harnest, MSc, BSc, as Chief Financial Officer. This key addition comes at a pivotal moment for Totus as the company prepares to advance its clinical-stage program following encouraging results from its Phase 1 study of TOS-358, a covalent PI3Kα inhibitor. "The addition of Simon, with over 15 years' experience in private capital markets strategy and IPO processes, comes at the right time for Totus as we advance our clinical-stage and discovery programs," said

      1/28/25 8:00:00 AM ET
      $CBUS
      $CLLS
      $MGX
      $CLXT
      Agricultural Chemicals
      Industrials
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Calyxt Names IBM's Global Chief Artificial Intelligence Officer, Dr. Seth Dobrin, to Scientific Advisory Board

      ROSEVILLE, Minn., Oct. 12, 2021 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT), a plant-based synthetic biotechnology company, today announced the appointment of Seth Dobrin, Ph.D., to the Company's Scientific Advisory Board (SAB). Dr. Dobrin is the Global Chief Artificial Intelligence (AI) Officer at IBM and brings extensive leadership experience and a track record of transforming companies through data and AI. "We warmly welcome Seth to our Scientific Advisory Board. Seth is a visionary whose deep experience bringing AI-based business solutions to major global corporations will be invaluable as we continue to develop and augment the AI and machine learning (AIML) capabilities of our PlantSprin

      10/12/21 7:00:00 AM ET
      $CLXT
      Agricultural Chemicals
      Industrials
    • Calyxt Appoints Michael A. Carr as Chief Executive Officer

      ROSEVILLE, Minn., July 15, 2021 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT), a plant-based biotechnology platform company, today announced the appointment of Michael A. Carr as President and Chief Executive Officer, effective July 27, 2021. Mr. Carr will also serve as a member of Calyxt's Board of Directors. Mr. Carr was most recently the Vice President of M&A, Strategy, and Innovation at Darling Ingredients, Inc., a global developer and producer of sustainable natural ingredients and renewable energy. "Michael's operational, financial, and investment experience, paired with his diverse knowledge across industries including health, nutrients, bioenergy and services will be integral as we adva

      7/15/21 4:01:00 PM ET
      $CLXT
      Agricultural Chemicals
      Industrials

    $CLXT
    SEC Filings

    See more
    • Calyxt Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Cibus, Inc. (0001705843) (Filer)

      1/9/24 4:47:04 PM ET
      $CLXT
      Agricultural Chemicals
      Industrials
    • Calyxt Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

      8-K - Cibus, Inc. (0001705843) (Filer)

      1/2/24 7:15:59 AM ET
      $CLXT
      Agricultural Chemicals
      Industrials
    • SEC Form 424B5 filed by Calyxt Inc.

      424B5 - Cibus, Inc. (0001705843) (Filer)

      1/2/24 7:07:41 AM ET
      $CLXT
      Agricultural Chemicals
      Industrials